Ceftaroline: A cephalosporin with Anti-MRSA activity

Clinical Microbiology Newsletter

Volumn 33, Issue 21, 2011, Pages 161-169

  Yee, Cheung ^a   Biek, Donald ^b   Krause, Kevin ^b   Williams, Gregory ^b  

^a FOREST RESEARCH INSTITUTE   (United States)

^b Cerexa Inc (a wholly owned subsidiary of Forest Laboratories Inc)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFTAROLINE; CEFTAROLINE FOSAMIL; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; TOBRAMYCIN; VANCOMYCIN;

AGAR DILUTION; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; DISK DIFFUSION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTERACTION; DRUG MECHANISM; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECALIS; EPSILOMETER TEST; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM BACTERICIDAL CONCENTRATION METHOD; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PENICILLIN RESISTANCE; QUALITY CONTROL; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 80054903540     PISSN: 01964399     EISSN: 18734391     Source Type: Journal    
DOI: 10.1016/j.clinmicnews.2011.10.001     Document Type: Article

References (37)

1. Ishikawa T., et al. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorg. Med. Chem. 2003, 11:2427-2437.
2. Zhanel G.G., et al. Ceftaroline: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Drugs 2009, 69:809-831.
3. Teflaro (ceftaroline fosamil) prescribing information 2011, Forest Laboratories, Inc., New York, NY.
4. Villegas-Estrada A., et al. Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics. J. Am. Chem. Soc. 2008, 130:9212-9213.
5. Kosowska-Shick K., McGhee P.L, Appelbaum P.C. Affinity of ceftaroline and other β-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 2010, 54:1670-1677.
6. Moisan H., Pruneau M., Malouin F. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J. Antimicrob. Chemother. 2010, 65:713-716.
7. Zervosen, A. et al. 2009. Enzymatic inhibition of Streptococcus pneumoniae PBP 2x transpeptidase activity by ceftaroline, poster P-1105. Presented at the European Congress of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
8. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; 20th informational supplement M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Bhavnani, S.M. et al. 2011. Pharmacokinetic-pharmacodynamic (PK-PD) target attainment (TA) analysis to evaluate susceptibility test interpretive criteria for ceftaroline (CPT) against Staphylococcus aureus (SA) (poster). Presented at Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
10. Van Wart, S.A. et al. 2011. Use of ceftaroline (CPT) against Streptococcus pneumoniae (SP): pharmacokinetic-pharmacodynamic (PK-PD) target attainment (TA) analysis to evaluate susceptibility test interpretive criteria (poster). Presented at Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
11. Tygacil (tigecycline) prescribing information 2011, Wyeth Pharmaceuticals Inc., Philadelphia, PA.
12. Zyvox (linezolid) prescribing information 2010, Pfizer, Inc., New York, NY.
13. Rocephin (ceftriaxone sodium) prescribing information 2010, Genentech USA, Inc., South San Francisco, CA.
14. Vancomycin hydrochloride prescribing information 2007, Hospira Inc., Lake Forest, IL.
15. Levaquin (levofloxacin) prescribing information 2011, Ortho-McNeil, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., Raritan, NJ.
16. Zosyn (piperacillin and tazobactam) prescribing information 2009, Wyeth Pharmaceuticals Inc., Philadelphia, PA.
17. Cubicin (daptomycin) prescribing information 2010, Cubist Pharmaceuticals, Inc., Lexington, MA.
18. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing; 21st informational supplement M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.
19. Citron, D.M. and E.J.C. Goldstein. 2008. Effects of in vitro test method variables on ceftaroline activity against aerobic gram-positive and gram-negative pathogens, poster D-2232. Intersci. Conf. Antimicrob. Agents Chemother./Infect. Dis. Soc. Am. American Society for Microbiology, Washington, DC.
20. Jones R.N., et al. Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. J. Antimicrob. Chemother. 2005, 56:1047-1052.
21. Schubert, S., and A. Dalhoff. 2011. Evaluation of the effect of protein on the antibacterial activity and pharmacodynamics of ceftaroline, poster P792. Presented at the European Congress of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
22. Clinical and Laboratory Standards Institute Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically - 8th ed. Approved standard M07-A8 2009, Clinical and Laboratory Standards Institute, Wayne, PA.
23. Clinical and Laboratory Standards Institute Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically - 6th ed. Approved standard M07-A7 2006, Clinical and Laboratory Standards Institute, Wayne, PA.
24. Bastulli, C. et al. 2008. An equivalency study of the Sensititre dried MIC system compared with the CLSI broth dilution reference method for ceftaroline and comparator antimicrobials, poster A-003. Presented at the American Society for Microbiology General Meeting. American Society for Microbiology, Washington, DC.
25. Killian, S.B. et al. 2009. A multi-site study of the Sensititre susceptibility system compared with the CLSI microdilution method for MIC determination of gram-negative and gram-positive organisms vs. ceftaroline, poster C-015. Presented at the American Society for Microbiology General Meeting. American Society for Microbiology, Washington, DC.
26. Mushtaq S., et al. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J. Antimicrob. Chemother. 2007, 60:300-311.
27. Engelhardt, A. et al. 2008. Comparative evaluation of ceftaroline MIC testing with Etest and CLSI broth microdilution methods, poster D-2249. Presented at the Intersci. Conf. Antimicrob. Agents Chemother./Infect. Dis. Soc. Am. American Society for Microbiology, Washington, DC.
28. U.S. Food and Drug Administration Approval letter to market Hardy Disk Ceftaroline 30 μg Accessed 1 August 2011. http://www.accessdata.fda.gov/cdrh_docs/pdf10/K103538.pdf.
29. Clinical and Laboratory Standards Institute Performance standards for antimicrobial disk susceptibility tests - 10th ed 2009, M02-A10. Clinical and Laboratory Standards Institute, Wayne, PA.
30. Brown S.D., Traczewski M.M. In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing. Antimicrob. Agents Chemother. 2009, 53:1271-1274.
31. Sader, H.S. et al. 2006. Evaluation of the bactericidal activity of the novel cephalosporin ceftaroline (PPI-0903M) compared to ceftriaxone against Streptococcus pneumoniae, poster E-0121. Presented at the Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
32. Saravolatz L., Pawlak J., Johnson L. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 2010, 54:3027-3030.
33. Vidaillac C., et al. In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2009, 53:2360-2366.
34. Vidaillac C., Leonard S.N., Rybak M.J. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates. Int. J. Antimicrob. Agents 2010, 35:527-530.
35. Schaadt, R.D. et al. 2007. In vitro evaluation of the antibacterial activity of ceftaroline in combination with other antibacterial agents, poster E-279. Presented at the Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
36. Clark C., et al. Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria. Antimicrob. Agents Chemother. 2011, 55:2344-2351.
37. Hinshaw, R.R. et al. 2008. Spontaneous mutation frequency and serial passage resistance development studies with ceftaroline, poster C1-185. Presented at the Intersci. Conf. Antimicrob. Agents Chemother./Infect. Dis. Soc. Am. American Society for Microbiology, Washington, DC.